Aurobindo Pharma shares gain on USFDA nod for osteoporosis drug

By: |
New Delhi | Published: March 21, 2016 4:29:59 PM

Aurobindo Pharma shares gained over 3 per cent on Monday after it announced that the company has received final approval from USFDA to manufacture and market Naproxen Sodium Tablets

aurobindo pharma, sensexAurobindo Pharma shares gained over 3 per cent on Monday after it announced that the company has received final approval from USFDA to manufacture and market Naproxen Sodium Tablets

Aurobindo Pharma shares gained over 3 per cent on Monday after the pharma company on Saturday announced that it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Naproxen Sodium Tablets used for treatment of osteoporosis. The product is expected to be launched in Q1 FY16-17.

The share price of Aurobindo Pharma closed 3.06 per cent up at Rs 742.95. The scrip opened at Rs 728.90 and touched a high and low of Rs 748.20 and Rs 728.55, respectively, in trade so far. Sensex closed 1.33 per cent, or 332.63 points, up at 25,285.37.

In a BSE filing, Aurobindo Pharma said, “The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Naproxen Sodium tablets USP, 220 mg.”

For the quarter ended December 2015, the company reported a consolidated net profit of Rs 534.95 crore, up 39.18 per cent, against Rs 384.35 crore in the same quarter last year.

The promoters holding in the company stood at 53.90 per cent while institutions and non-institutions held 35.24 per cent and 10.86 per cent, respectively.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Sebi extends power of attorney norms implementation date to August 1
2When will private equity investments resume in India; at least this much more wait ahead
3Rights Entitlement: Sebi puts valuation prescription in place for subscription via renounced rights